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Abstract
Objective: the patch test (Pt) with its modification –
the strip patch test (sPt) – is the standard in vivo pro-
cedure  to  diagnose  an  allergic  contact  dermatitis
(AcD). to date, none of the in vitro tests for the diag-
nosis of AcD fulfils the requirements of an easy, valid
and reliable test. to investigate the prediction ability of
a  flow  cytometric  assay  of  cD69  up-regulation  on
cD4+ clA+ t cells in nickel-sensitive and non-nick-
el-sensitive patients.
Methods: In a prospective, investigator-blinded, clinical
study a total of 85 nickel-sensitive (n = 44; 51.8%) and
non-nickel-sensitive patients (n = 41; 48.2%) were en-
rolled.  the  association  between  cD69  up-regulation
on cD4+ clA+ t cells on the one hand and Pt, sPt,
and clinical history on the other hand was measured.
Association is expressed with c statistic values (receiv-
er operating characteristic analysis) and corresponding
95% cIs.
Results:  the  associations  were  c  =  0.57  (95%  cI:
0.42–0.72) between cD69 up-regulation and Pt, c =
0.49 (95% cI: 0.36–0.62) between cD69 up-regulation
and sPt, and c = 0.51 (95% cI: 0.37–0.64) between
cD69 up-regulation and clinical history.
Conclusions: cD69 up-regulation on cD4+ clA+ t
cells in vitro could not predict neither a positive Pt or
sPt result nor a positive clinical history to nickel sul-
fate.  the  combination  of  clinical  history  and  patch
testing still remains the basis for diagnosing AcD.
Key  words: Allergic contact dermatitis, nickel sulfate,
flow cytometric assay, cD69 up-regulation, patch test,
strip  patch  test,  clinical  history,  receiver  operating
characteristic
Abbreviations: AcD = Allergic contact dermatitis; AI
= Activation index; cD = cluster of differentiation;
cI = confidence interval; clA = cutaneous lympho-
cyte-associated  antigen;  D-PBs  =  Dulbecco’s  phos-
phate-buffered saline; Dc = Dendritic cells; Dts =
Delayed-type sensitization; ElIspot = Enzym-linked
immunospot;  fAcs  =  fluorescence-activated  cell
sorting; ltt = lymphocyte transformation test; mAb
= Monoclonal antibodies; MElIsAﾮ = Memory lym-
phocyte immuno-stimulation assay; PBMc = Periph-
eral blood mononuclear cells; PHA-P = Phytohemag-
glutinin; Pt = Patch test; Roc = Receiver operating
characteristic; sPt = strip patch test
IntRoDUctIon
since  its  inauguration  in  1895  by  Jadassohn  [1],  the
patch test (Pt) is believed to be the “gold standard” in
the  diagnosis  of  allergic  contact  dermatitis  (AcD).
However, the method of patch testing has repeatedly
been questioned [2-6] for its limited validity and repro-
ducibility and it is therefore by no means uniformly
accepted  as  a  reliable  test  method.  As  a  variant  of
patch  testing,  tape  stripping  the  skin  prior  to  patch
testing  was  first  mentioned  in  1953  by  spier  and
natzel  [7].  since  then,  the  strip  patch  test  (sPt)  is
used in some places to obtain more valid and reliable
test results [8-13].
Although a non-in vivo test would be desirable, to
date, none of the established in vitro tests for the di-
agnosis of AcD (e.g., ltt, MElIsAﾮ, ElIspot as-
say)  fulfils  the  requirements  of  a  practical  test  with
sufficient  validity  and  reliability  [5,  14-17].  An  ad-
vanced  approach  is  the  flow  cytometric  analysis  of
cD69  up-regulation  on  t  lymphocytes  in  vitro  [18-
21]. As previously reported, metal ions released from
orthopedic implants in patients with metal prostheses
increased the expression of cD69 activation antigen
on cD3+ lymphocytes considerably and flow cytome-
try proved to be an easy and reliable method for detec-
tion [19]. the expression of the cD69 activation anti-
gen on cD4+ t cells after stimulation with drugs has
been just recently evaluated in a pilot study and shown
to discriminate well between drug-allergic and non-al-
lergic patients [21].
Based on the additional findings of Moed et al. [22]
that  nickel-allergic  patients  are  characterized  by  a
cD4+  cD45Ro+  clA+  t  cell  phenotype,  we  de-
signed a study to analyze the extent of cD69 activa-
tion  antigen  expression  on  cD4+  clA+  t  cells  in
nickel-sensitive and non-nickel-sensitive patients using
flow cytometry. our flow cytometric assay would offer
some advantages over the classical ltt, as it provides
results after 72 h instead of 7 days and does not re-
quire 3H-thymidine incorporation. We measured asso-
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t cells on the one hand and Pt, sPt, and clinical his-
tory on the other hand.
MEtHoDs
the  prospective,  investigator-blinded,  clinical  study
was approved by the ethics committee of the Medical
faculty of the Ruhr University Bochum. Procedures
were explained in detail to all patients, who signed in-
formed consent forms prior to participation.
PAtIEnt REcRUItMEnt PRocEDURE
Patients had to be at least 18 years old and had to have
clinically normal skin. Exclusion criteria were pregnan-
cy, lactation, intake of immunosuppressive or immune
modulating  drugs  such  as  glucocorticoids  or  cy-
closporine, topical use of glucocorticoids at the back,
and intense UV exposure on the back within the last 4
weeks prior to patch testing, respectively.
to optimize statistical power and discrimination be-
tween Pt and sPt, patients were selected according to
their Pt and sPt results to nickel sulfate 5% pet. fol-
lowing a prespecified protocol. this aimed for half of
the study patients being Pt positive and sPt positive,
respectively. We defined patients as being “nickel-sen-
sitive” if either one of the patch tests was positive, or
if the clinical history indicated a delayed-type sensiti-
zation (Dts).
to  avoid  the  influence  of  a  positive  Pt  or  sPt,
blood samples were taken at least 6 weeks after patch
testing [22]. At the time of blood sample collection, in
any patient symptoms of Dts had subsided. All blood
tests were obtained between 2009-03-09 and 2009-07-
06; they were coded and performed within 2 h. Pa-
tients received a small allowance for taking of blood
samples.
PAtcH tEst AnD stRIP PAtcH tEst
Pt was performed according to standard methodolo-
gy  [23].  sPt  was  performed  according  to  our  stan-
dardized  method  described  in  details  elsewhere  [11,
12, 24]. tape stripping was carried out with a 3M™
Blenderm™ surgical tape (3M™ Medica, 3M Deutsch  -
land gmbH, neuss, germany; metric 25 mm ﾥ 4.5 m);
any body hair was removed before with a 3M™ clip-
per.
Patients were tested on the upper back with nickel
sulfate 5% pet. supplied by HERMAl, Reinbek, ger-
many. small finn chambers on scanporﾮ (Epitest ltd
oy, tuusula, finland) were used. Pt and sPt were ap-
plied to the left and right side of the upper back with
one randomly chosen side tape stripped for the sPt.
other patch test batteries were applied conventionally
as appropriate to the patient’s presenting complaints.
tests  were  uniformly  removed  after  24  hours  and
readings were routinely performed at D1 (24 h) and
D3 (72 h). Positive results are reported based on the
second reading. the tests results were graded using the
classification  system  of  the  IcDRg  [25]  and  di-
chotomized for statistical analysis. All “+”, “++”, and
“+++” positive results were summarized as positive
responses,  whereas  doubtful  “?/(+)”,  irritant  “IR”,
and  negative  “–”  reactions  counted  as  negative  re-
sponses.
clInIcAl HIstoRy
Dts to nickel sulfate was determined following an al-
gorithm that used information on four questions on (i)
intolerance to fashion jewelry, (ii) jeans button eczema,
(iii) hand eczema by working galvanic processes, and
(iv)  sensitization  proved  by  Pt  in  the  past.  Patients
were classified as to whether or not they had a Dts to
nickel sulfate based on their responses (“sensitized” by
definition if ≥ 2 questions were positively answered)
prior to undergoing the patch tests.
PBMc IsolAtIon AnD cUltURE
twenty milliliters of blood was collected from all the
patients and placed into two BD Vacutainerﾮ cPt™
cell preparation tubes with sodium heparin (Becton,
Dickinson  and  company,  nJ,  UsA;  no.  362753).
PBMc were isolated from heparinized blood samples
by  density  centrifugation  on  Heraeus  Megafuge 
16R (thermo scientific, MA, UsA) for 20 min at 1800
ﾥg.  the  collected  PBMc  were  washed  twice  with 
D-PBs  (Invitrogen  corporation,  cA,  UsA;  no.
14190)  by  centrifugation  for  6  min  at  250  ﾥg  and 
then  resuspended  in  culture  medium  composed  of
RPMI-1640  medium  supplemented  with  l-glutamine
(sIgMA-Aldrich company, Ayrshire, Uk; no. R8758),
10% autologous serum, and 1% stabilized antibiotic
antimycotic  solution  (sIgMA-Aldrich  company; 
no.  A5955).  PBMc  suspensions  at  a  concentration 
of 1 ﾥ 106 viable cells/ml were prepared; cell viability
was measured by exclusion of 0.4% trypan blue.
PBMc  (100  ﾵl)  were  plated  in  duplicate  (1  ﾥ
105/well)  in  96-well  flat-bottomed  plates  (greiner
Bio-one  gmbH, Essen, germany). stimuli were:
100  ﾵl  of  fresh  culture  medium  as  negative  control
(composed  as  mentioned  above),  100  ﾵl  of  each 
non-cytotoxic  nickel  sulfate  concentration  (10-5 M, 
2.6 ﾵg/ml; 10-6 M, 262.8 ng/ml; 10-7 M, 26.3 ng/ml),
and 100 ﾵl of each PHA-P concentration as positive
controls  (5.0  ﾵg/ml;  2.5  ﾵg/ml;  sIgMA-Aldrich 
company,  Ayrshire,  Uk;  no.  l1668).  cell  cultures
were  incubated  at  37  ﾰc  in  a  humidified  95%  air/
5%  co2 atmosphere  for  72  h  [21,  26]  (co2 water
jacketed  incubator  nU  4500E;  nuAire  Inc.,  Mn,
UsA).
the  raw  material  nickel  sulfate  hexahydrate
(niso4ﾷ6H2o;  cAs  no.  10101-97-0)  used  for  the 
fabrication  of  the  patch  test  substance  nickel 
sulfate  5%  pet.  was  purchased  from  HERMAl, 
Reinbek,  germany.  the  freshly  prepared  stock 
solution  of  nickel  sulfate  (10-2 M,  2.6  mg/ml) 
was  centrifuged  and  filtered  onto  0.22  ﾵm  pore 
filter  in  order  to  eliminate  any  particulate  residual. 
In  preliminary  sets  of  samples  (n  =  12;  data  not
shown)  higher  concentrations  of  nickel  sulfate 
(10-3 M,  262.8  ﾵg/ml;  10-4 M,  26.3  ﾵg/ml)  showed 
cytotoxic  effects  whereas  lower  concentrations 
(10-8 M,  2.6  ng/ml;  10-9 M,  262.8  pg/ml)  showed 
no effects.
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UP-REgUlAtIon
After incubation the PBMc were washed with D-PBs
and then surface stained for 30 min in the dark at 4 ﾰc
with a suspension of mAb for detection of cD69-ac-
tivated  cD4+  clA+  t  cells:  anti-clA-fItc/anti-
cD4-PE-cy7/anti-cD45-PercP-cy5.5/anti-cD69-
APc/anti-cD3-APc-H7 (BD Biosciences, cA, UsA).
the proportion of cD45/cD3/cD4/clA/cD69-
positive PBMc was evaluated on ≥ 20,000 events with-
in the scatter gate cD3 using a 3 laser (488, 405, 633
nm) 8 parameter fAcscanto™ II flow cytometer with
fAcsDiva™ software  (BD  Biosciences,  cA,  UsA).
the results were normalized for heterogeneous back-
ground proliferation. thus, a ratio (“activation index“,
AI)  [19]  between  the  percentage  of  cD45/
cD3/cD4/clA/cD69-positive  cells  stimulated  with
nickel sulfate and the percentage of the control cells
stimulated  with  culture  medium  only  was  expressed.
An AI value < 0.9 may be interpreted as “low activa-
tion”, ≥ 0.9 and < 2 as “normal activation”, and ≥ 2 as
“high activation”/”positive” [19, 21, 26]. We used the
maximum AI across the three nickel sulfate concentra-
tions (10-5 M, 10-6 M, 10-7 M) for statistical analysis.
BlInDIng
the reading physician (H.D.) was blinded with respect
to (i) the clinical history and (ii) which side of the pa-
tient’s back was tape stripped. Unblinding was done
after the second reading for clinical interpretation of
test results. the laboratory technician performing the
flow cytometric assay of cD 69 up-regulation (s.H.)
was blinded with respect to (i) the clinical history and
(ii) the patch test results.
stAtIstIcAl AnAlysIs
for  descriptive  purposes,  we  report  categorical  vari-
ables as absolute (relative) frequencies, and continuous
variable as median (min-max, Q1, Q3). to measure as-
sociation between flow cytometric assay of cD 69 up-
regulation  (maximum  AI)  on  the  one  hand  and  Pt,
sPt, and clinical history on the other hand, we applied
Roc analysis and the corresponding c statistic measur-
ing the area under the Roc curve. the c statistic can
be conveniently interpreted as the probability of a Pt
positive (or sPt positive, or clinical history positive)
patient having a larger maximum AI, than a Pt nega-
tive (or sPt negative, or clinical history negative) pa-
tient. thus, values of the c statistic of 0.5 corresponds
to purely random association, whereas values of 0 or 1
correspond to a perfect association. All c statistics are
given with the respective 95% cIs. statistical analyses
were conducted with sAsﾮ (sAs Institute, cary, nc,
UsA), Version 9.2., where the newly introduced Roc
statement  in  the  logIstIc  procedure  allows  Roc
analysis and calculates cIs for the c statistic.
REsUlts
Demographic  and  clinical  characteristics  of  the  85
nickel-sensitive (n = 44; 51.8%) and non-nickel-sensi-
tive patients (n = 41; 48.2%) enrolled in the study are
summarized in table 1.
AssocIAtIon of tHE floW cytoMEtRIc AssAy of
cD 69 UP-REgUlAtIon VERsUs Pt, sPt AnD
clInIcAl HIstoRy
there was no association between the extent of cD69
activation antigen expression on cD4+ clA+ t cells
in vitro and Pt, sPt, and clinical history. c statistics
differed only marginally from the value of no associa-
tion, which is 0.5 (fig. 1 A-c).
PREDIctIon of sEnsItIzAtIon By Pt sPt, AnD floW
cytoMEtRIc AssAy of cD 69 UP-REgUlAtIon
In  relation  to  the  clinical  history,  Pt  alone  predicts
satisfyingly the sensitization to nickel sulfate (c = 0.69,
95% cI: 0.59–0.79). the prediction accuracy could be
improved  significantly  to  good  by  additionally  per-
forming the sPt (c = 0.83, 95% cI: 0.74–0.92). How-
ever, no further diagnostic information could be gath-
ered by additionally using the results of the flow cyto-
metric assay of cD69 up-regulation on cD4+ clA+
t cells (c = 0.83, 95% cI: 0.74–0.93).
DIscUssIon
In the present study the flow cytometric assay of cD69
up-regulation on cD4+ clA+ t cells could not pre-
dict neither a positive Pt or sPt result nor a positive
clinical history to nickel sulfate (fig. 1 A-c). on the
contrary, we found relevant improvements in prediction
of clinical history-based nickel sensitization beyond Pt
by the sPt, but not by our flow cytometric assay.
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Table 1. Demographic and clinical patient characteristics (n =
85).
Characteristic Value
Age (years), median (min-max, Q1, Q3) 53 (18-75, 44, 60)
sex, n (%)
female 60 (70.6)
male 25 (29.4)
Fitzpatrick skin phototype, n (%)
I 1 (1.2)
II 64 (75.2)
III 19 (22.4)
IV 1 (1.2)
V, VI 0 (0)
CD69 up-regulation by Ni stimulation
AI*, median (min-max, Q1, Q3) 2.5(0.3-61.0,1.5, 5.7)
Positive skin reaction to Ni, n (%)
in Pt on D3 21 (24.7)
in sPt on D3 37 (43.5)
Positive clinical history to Ni, n (%) 31 (36.5)
Q1 = 25th percentile; Q3 = 75th percentile; ni = nickel sulfate;
D3 = second reading at 72 h; * = AI is defined as the maxi-
mum AI across the three nickel sulfate concentrations (10-5 M,
10-6 M, 10-7 M).
5. Dickel_Umbruchvorlage  12.07.10  14:31  Seite 305In the in vitro tests so far, the response of PBMc
to nickel sulfate generally appeared to be variable, and
at best weakly correlated with the Pt response [27,
28]. Association with the sPt response was never in-
vestigated before. nevertheless, the Pt is usually the
reference  standard  against  which  in  vitro  tests  are
compared  [14,  15,  27,  29],  despite  its  numerous
methodological  drawbacks  (e.g.,  false-positive  and
false-negative test results) [20]. only few authors have
like us additionally focused on assessing association of
in vitro tests and clinical history [30].
MEtHoDologIcAl AsPEcts concERnIng tHE
DIscoRDAnt REsUlts
first, the basis of the study was the observation of
Moed et al. [22] that cD4+ cD45Ro+ clA+ and not
cD8+ t cells proliferate and produce cytokines in re-
sponse  to  nickel.  Additionally,  they  confirmed  that
clA can serve as a preselection marker to improve
detection of antigen-specific t cells in patients with
suspected AcD. In the initial sensitization phase, naive
t cells in the regional lymph nodes are primed by local
antigen-bearing Dc and expand clonally [31, 32]. By
expressing clA which is a specific chemokine recep-
tor involved in lymphocyte homing to skin, these t
cells  are  then  enabled  to  circulate  throughout  the
blood into the dermis [19, 33, 34]. In the following
elicitation  phase,  the  t-cell  mediated  AcD  reaction
occurs normally 24-72 h after re-exposure to antigen
[32]. Within the first 24 hours, the integral membrane
protein cD69 is transiently expressed on the antigen-
specific t cells and acts as a co-stimulator for t cell
activation and proliferation. thus, it was reasonable to
postulate that an expression assay of cD69 on cD4+
clA+  t  cells  is  a  promising  readout  test  of  Dts.
However,  we  omitted  staining  with  anti-cD45Ro-
fItc due to a too high restriction resulting in a small
number of analyzable t cells. second, it is reported
that nickel sulfate has in contrast to other metal salts
non-specific stimulatory properties in vitro which still
is a major problem [14, 15, 17]. In our study we ob-
tained the raw material of nickel sulfate hexahydrate
straight from the production process of the patch test
substance and the highest concentration used for stim-
ulation was 2.6 ﾵg/ml [14]. thus, a cytotoxic or mito-
genic effect of the nickel concentrations should be un-
likely because concentrations of nickel sulfate greater
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Fig. 1. Area under the Roc curve (c statistic) for flow cyto-
metric assay of cD69 up-regulation predicting in vivo test re-
sults (A, B) and clinical history (c).
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tain non-sensitized individuals, i.e. induce false posi-
tive test results [27, 29]. Additionally, from our data
(median AI = 2.5, table 1) it is unlikely that the flow
cytometric  assay  of  cD69  up-regulation  on  cD4+
clA+ t cells produced false negative test results be-
cause of a too weak activation of t cells by nickel sul-
fate [21].
BIologIcAl AsPEcts concERnIng tHE DIscoRDAnt
REsUlts
first, Beeler et al. [21] showed only recently that flow
cytometric  measurement  of  cD69  up-regulation  on
cD4+ t cells is a promising alternative to ltt in di-
agnosing drug hypersensitivity. However, they report-
ed that the high frequency of activated t cells could
not be explained by a rapid expansion of few drug re-
active t cells and that only up to 5% of cD69+ t
cells reacted to drug stimulation with cytokine produc-
tion. thus, they distinguished between two subsets of
t cells: (i) few drug-reactive t cells, which are most
likely identical to the proliferating and/or cytokine-se-
creting  t  cells,  and  (ii)  many  drug-activated  “by-
stander” t cells, which reacted to cytokines secreted
by the “truly” drug-specific t cells. from this they ar-
gued that this does not affect the specificity of the
test, but substantially increases its sensitivity. second, a
positive in vitro test together with a negative Pt or
sPt could be explained by the fact that nickel-specific
t cells were found in patients without nickel allergy
[14]. on the contrary, there is a positive Pt or sPt
and a negative in vitro test which might theoretically
be due to nickel-specific cells homing to the site of lo-
cal skin reaction. finally, different t cell subsets may
be activated in vitro and in vivo upon contact with
nickel  sulfate  and  could  explain  non-correlating  test
results [32].
conclUsIon
the flow cytometric assay of cD69 up-regulation on
cD4+ clA+ t cells as an alternative to existing in
vitro tests is no help for diagnosing AcD to nickel. In
consequence, the combination of clinical history and
patch test results continues to be the basis for the di-
agnosis of AcD [17]. further studies are needed in
search of an innovative in vitro test method with suffi-
cient discrimination between allergic and non-allergic
patients [26].
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